Keywords: Biosimilars, Market forecasts, Sandoz, Hospira, Dr Reddy's, MAbs, Visiongain

"Sandoz will be the leading biosimilars company in 2012," says Visiongain

Article | 04 October 2012

Print This

Sandoz, the generics unit of Swiss drug major Novartis (NVN: VX), will retain its position as the global leader in ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in